This 5-year Horizon Cancer Mission project was launched in January 2024, with the ambitious goal of establishing liquid biopsies as standard-of-care to monitor relapsed/refractory neuroblastoma and as a blueprint for other paediatric cancers. This groundbreaking initiative sets the stage for improving care in other paediatric cancers. Unlike traditional methods like imaging and bone marrow assessments, which are invasive and challenging for children, liquid biopsies provide a safer, simpler, and more child-friendly solution to address key challenges in paediatric oncology.
The project gathers a group of 25 multi-stakeholder partners from 11 European countries, including research centres, patient advocacy organizations, specialty societies, and small to medium enterprises.
In 2024, MONALISA received widespread recognition at numerous international events, including the SIOP Europe Annual Meeting in Milan, the SIOPEN Annual General Meeting in Vilnius, and the Pediatric AACR in Toronto.
Two key project events took place in January:
- MONALISA General Assembly - 29 January 2025, Utrecht, the Netherlands.
This Meeting served as an opportunity to update project partners on the work carried out in 2024 and plan for the coming year;
- Diagnosis & Treatment (diagnostics) Cluster Meeting - 16-17 January 2025.
The meeting aimed at addressing common scientific challenges and was organised in close collaboration with the European Commission.
If you wish to stay updated about MONALISA, we invite you to subscribe to our biannual Newsletter on the project webpage.
For more information about MONALISA we also invite you to visit the SIOP Europe Social Media on X, LinkedIn, Facebook and YouTube.